Lactate dehydrogenase A mRNA (LDHA mRNA)

Lactate dehydrogenase A (LDHA) mRNA is the messenger RNA transcript that encodes the LDHA enzyme, a key protein involved in the final step of anaerobic glycolysis and glyoxylate metabolism (UniProt P00338). In the liver, LDHA facilitates the conversion of glyoxylate to oxalate; therefore, targeting its mRNA is a strategic approach to treat Primary Hyperoxaluria (PH) by reducing toxic oxalate accumulation (Hoppe et al., 2021, Lancet Diabetes & Endocrinology). The therapeutic agent Nedosiran (Rivfloza) is a double-stranded siRNA that specifically targets LDHA mRNA in hepatocytes, utilizing the RNA interference (RNAi) pathway to induce mRNA degradation (FDA, 2023). This mechanism effectively lowers hepatic LDHA protein levels and subsequently decreases urinary oxalate excretion in patients with PH (Liebow et al., 2022, Journal of the American Society of Nephrology). Additionally, LDHA mRNA is a target of interest in oncology because the encoded enzyme is central to the Warburg effect, where cancer cells prioritize lactate production to support rapid growth (Valvona et al., 2016, Reviews in Cancer). Inhibiting LDHA expression via mRNA-targeting strategies represents a novel frontier in managing both metabolic and malignant diseases.

Other names

LDHA transcriptL-lactate dehydrogenase A chain mRNALactate dehydrogenase M-chain mRNALDH-A mRNA

RNA interference (RNAi) leading to the degradation of the target mRNA and subsequent reduction in protein expression (FDA, 2023).